Market closedADR
GENFIT/$GNFT
14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX
About GENFIT
Genfit SA is a biotechnology company focused on metabolic and inflammatory diseases, with a particular focus on the liver and gastroenterology. The company's research and development activity relies on its expertise in modulating gene expression through nuclear receptors. Genfit utilizes acquisitions, strategic alliances, and licensing agreements in order to fund the further development of its products. It has one segment the research and development of innovative medicines and diagnostic solutions, the marketing of which depends on the success of the clinical development phase.
Ticker
$GNFT
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
169
Website
GENFIT Metrics
BasicAdvanced
$187M
Market cap
8.35
P/E ratio
$0.46
EPS
1.09
Beta
-
Dividend rate
Price and volume
Market cap
$187M
Beta
1.09
52-week high
$6.24
52-week low
$3.31
Average daily volume
7.2K
Financial strength
Current ratio
3.744
Quick ratio
3.642
Long term debt to equity
61.405
Total debt to equity
69.64
Interest coverage (TTM)
4.31%
Management effectiveness
Return on assets (TTM)
6.51%
Return on equity (TTM)
25.91%
Valuation
Price to earnings (TTM)
8.354
Price to revenue (TTM)
2.254
Price to book
1.83
Price to tangible book (TTM)
3.53
Price to free cash flow (TTM)
-4.241
Growth
Revenue change (TTM)
175.45%
Earnings per share change (TTM)
-163.31%
3-year revenue growth (CAGR)
136.69%
3-year earnings per share growth (CAGR)
-22.81%
What the Analysts think about GENFIT
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for GENFIT stock.
GENFIT Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
GENFIT Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
GENFIT News
AllArticlesVideos
GENFIT Announces Corporate Updates and Upcoming Participation at The Liver Meeting® 2024
GlobeNewsWire·1 month ago
GENFIT Reports Third Quarter 2024 Financial Information
GlobeNewsWire·1 month ago
GENFIT: Ipsen's Iqirvo® (Elafibranor) Receives EU Approval as a First-in-Class Treatment for Primary Biliary Cholangitis following U.S. FDA Accelerated Approval
GlobeNewsWire·3 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for GENFIT stock?
GENFIT (GNFT) has a market cap of $187M as of December 14, 2024.
What is the P/E ratio for GENFIT stock?
The price to earnings (P/E) ratio for GENFIT (GNFT) stock is 8.35 as of December 14, 2024.
Does GENFIT stock pay dividends?
No, GENFIT (GNFT) stock does not pay dividends to its shareholders as of December 14, 2024.
When is the next GENFIT dividend payment date?
GENFIT (GNFT) stock does not pay dividends to its shareholders.
What is the beta indicator for GENFIT?
GENFIT (GNFT) has a beta rating of 1.09. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.